Quinolone derivatives as antitubercular drugs

An Overview of Various Rifampicin Analogs against Mycobacterium tuberculosis and their Drug Interactions

The success of the TB control program is hampered by the major issue of drug-resistant tuberculosis (DR-TB). The situation has undoubtedly been made more difficult by the widespread and multidrug-resistant (XDR) strains of TB. The modification of existing anti-TB medications to produce derivatives that can function on resistant TB bacilli is one of the potential techniques to overcome drug resistance affordably and straightforwardly. In comparison to novel pharmaceuticals for drug research and progress, these may have a better half-life and greater bioavailability, be more efficient, and serve as inexpensive alternatives. Mycobacterium tuberculosis, which is drugsusceptible or drug-resistant, is effectively treated by several already prescribed medications and their derivatives. Due to this, the current review attempts to give a brief overview of the rifampicin derivatives that can overcome the parent drug's resistance and could, hence, act as useful substitutes. It has been found that one-third of the global population is affected by M. tuberculosis. The most common cause of infection-related death can range from latent TB to TB illness. Antibiotics in the rifamycin class, including rifampicin or rifampin (RIF), rifapentine (RPT), and others, have a special sterilizing effect on M. tuberculosis. We examine research focused on evaluating the safety, effectiveness, pharmacokinetics, pharmacodynamics, risk of medication interactions, and other characteristics of RIF analogs. Drug interactions are especially difficult with RIF because it must be taken every day for four months to treat latent TB infection. RIF continues to be the gold standard of treatment for drug-sensitive TB illness. RIF's safety profile is well known, and the two medicines' adverse reactions have varying degrees of frequency. The authorized once-weekly RPT regimen is insufficient, but greater dosages of either medication may reduce the amount of time needed to treat TB effectively.

Mycobacterium tuberculosis: Pathogenesis and therapeutic targets

Tuberculosis (TB) remains a significant public health concern in the 21st century, especially due to drug resistance, coinfection with diseases like immunodeficiency syndrome (AIDS) and coronavirus disease 2019, and the lengthy and costly treatment protocols. In this review, we summarize the pathogenesis of TB infection, therapeutic targets, and corresponding modulators, including first-line medications, current clinical trial drugs and molecules in preclinical assessment. Understanding the mechanisms of Mycobacterium tuberculosis (Mtb) infection and important biological targets can lead to innovative treatments. While most antitubercular agents target pathogen-related processes, host-directed therapy (HDT) modalities addressing immune defense, survival mechanisms, and immunopathology also hold promise. Mtb's adaptation to the human host involves manipulating host cellular mechanisms, and HDT aims to disrupt this manipulation to enhance treatment effectiveness. Our review provides valuable insights for future anti-TB drug development efforts.

Multi-catalysis induced by pulsed discharge plasma coupled with graphene-Fe3O4 nanocomposites for efficient removal of ofloxacin in water: Mechanism, degradation pathway and potential toxicity

Herein, degradation of ofloxacin (OFX) by pulsed discharge plasma (PDP) coupled with multi-catalysis using graphene-Fe₃O₄ nanocomposites was inspected. The graphene-Fe₃O₄ nanocomposites were prepared by hydrothermal synthesis, and their morphology, specific surface area, chemical bond structure and magnetic property were characterized systematically. Compared with sole Fe₃O₄, the specific surface area of graphene-Fe₃O₄ nanocomposites increased from 26.34 m²/g to 125.04 m²/g. The prepared graphene-Fe₃O₄ nanocomposites had higher paramagnetism and the magnetic strength reached 66.05 emu/g, which was prone to separate from solution. Graphene-Fe₃O₄ nanocomposites could further accelerate OFX degradation compared to sole Fe₃O₄. When graphene content was 18 wt%, graphene-Fe₃O₄ nanocomposites exhibited the highest catalytic activity, and the removal efficiency of OFX enhanced from 65.0% (PDP alone) to 99.9%. 0.23 g/L dosage and acid solution were beneficial for OFX degradation. Higher stability of graphene-Fe₃O₄ nanocomposites could be maintained although four times use. Graphene-Fe₃O₄ nanocomposites could catalyze H₂O₂ and O₃ to produce more ·OH. The degradation products of OFX were identified by liquid chromatography mass spectrometry (LC-MS) and ion chromatography (IC). According to the identified products and discrete Fourier transform (DFT), the degradation pathway was inferred. Further toxicity assessment of products manifested that the toxicity of oral rat 50% lethal dose (LD₅₀) and the developmental toxicity of OFX were reduced.

Recent Synthetic Approaches and Biological Evaluations of Amino Hexahydroquinolines and Their Spirocyclic Structures

In this review, the recent synthetic approaches of amino hexahydroquinolines and their spirocyclic structures were highlighted. The synthetic routes include, two-components, three-components or fourcomponents reactions. The two-component [3+3] atom combination reaction represents the simplest method. It involves Michael addition of the electron rich β-carbon of β-enaminones to the activated double bond of cinnamonitriles followed by cyclization to yield hexahydroquinoline compounds. The bioactivity profiles and SAR studies of these compounds were also reviewed with emphasis to the utility of these substances as antimicrobial, anticancer and antitubercular agents, as well as calcium channel modulators.

Synthesis and In vitro Antibacterial, Antitubercular Studies of Novel Fluoroquinolones Analogs Containing 4-substituted Sec Amine

Background:

Tuberculosis is a contagious, air borne disease and second leading cause of death among infectious diseases worldwide. Fluoroquinolones are well-known antibacterial agents and they were recommended as second-line of antitubercular drugs.

Method:

A series of novel fluoroquinolone analogs 6-24 was effectively synthesized. An attempt was made by tagging the substituted pyrazole on to fluoroquinolones for the first time at C-7 position. The newly synthesized compounds were characterized by FTIR, 1HNMR, ESI-MS, HR-MS and elemental analysis. The in vitro antibacterial activity of all the title compounds was investigated against various gram positive, gram negative bacterial organisms and in vitro antitubercular activity against Mycobacterium Tuberculosis H37Rv strain.

Result:

Most of the synthesized compounds showed comparable activity against the entire gram positive and gram negative bacterial organisms. Fluoroquinolone 16 showed enhanced activity against both type of bacterial strains and compound 11showed promising activity against MTB-H37Rv strain.

Conclusion:

Some of the novel fluoroquinolone analogs (11, 16) showed potent antibacterial, antitubercular activity.

Oxidation of quinolones with peracids (an in situ EPR study)

4-Oxoquinoline derivatives (quinolones) represent heterocyclic compounds with a variety of biological activities, along with interesting chemical reactivity. The quinolone derivatives possessing secondary amino hydrogen at the nitrogen of the enaminone system are oxidized with 3-chloroperbenzoic acid to nitroxide radicals in the primary step while maintaining their 4-pyridone ring. Otherwise, N-methyl substituted quinolones also form nitroxide radicals coupled with the opening of the 4-pyridone ring in a gradual oxidation of the methyl group via the nitrone-nitroxide spin-adduct cycle. This was confirmed in an analogous oxidation using N,N-dimethylaniline as a model compound. N-Ethyl quinolones in contrast to its N-methyl analog form only one nitroxide radical without a further degradation.